All presentations will be in English. 

In his talk, Yannick Waumans will try to summarize the present and future state of predictive biomarkers in immune therapy. In the current status quo, most clinical trials rely on a single PD-L1 immunehistochemistry test to select patients for checkpoint inhibitor therapy. Beyond the problems with only interrogating a single parameter at a single timepoint in an otherwise highly dynamic context, there are many other issues with the current state of PD-L1 testing. These are of a more practical nature and, although seemingly trivial, they have had broad implications. Although many challenges still lie ahead, new strategies are being investigated that will be better suited at selecting those patients that will respond to therapy and that will go well beyond a single-parameter assay.